PureTech Health plc (LON:PRTC – Get Free Report)’s stock price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 123.28 and traded as high as GBX 131.20. PureTech Health shares last traded at GBX 130.60, with a volume of 5,188,465 shares changing hands.
PureTech Health Price Performance
The company has a debt-to-equity ratio of 6.33, a quick ratio of 2.51 and a current ratio of 6.59. The firm has a market capitalization of £320.34 million, a price-to-earnings ratio of -2.86 and a beta of 1.40. The business has a fifty day moving average of GBX 123.28 and a two-hundred day moving average of GBX 125.64.
PureTech Health Company Profile
PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule. It is also developing technology and products for screening, diagnosis, and treatment of neurological disorders, such as ADHD, autism, and depression through computer software; noninvasive neurostimulation treatment for psychiatric disorders; and combination therapy for schizophrenia.
Read More
- Five stocks we like better than PureTech Health
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
